TG Therapeutics Inc.

TGTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$57.16

+$0.29 (+0.51%)

At close: Sep 21, 2026, 4:00 PM ET

$57.30

+$0.14 (+0.24%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $8.71B

Enterprise Value $8.95B

Beta 1.66

Average Volume 2.34M

Shares Outstanding (Diluted) 157.28M

Shares Change YoY -3.25%

Institutional Ownership 73.00%

Exchange NASDAQ

ISIN US88322Q1085

Price Performance

Price Change 1M 7.5%

Price Change 3M 6.0%

Price Change 6M 79.6%

Price Change YTD 95.2%

Price Change 1Y 63.5%

Price Change 3Y 525.4%

Price Change 5Y 77.7%

1M CAGR (ann.) 14.8%

1Y CAGR (ann.) 77.5%

5Y CAGR (ann.) 13.8%

All-Time CAGR -8.1%

Valuation

PE Ratio 20.86

Forward PE 20.39

PEG Ratio 0.03

Forward PEG 0.10

PS Ratio 10.94

Forward PS 6.60

PB Ratio 14.49

P/FCF Ratio -15,625.46

P/Adj. FCF Ratio -86.06

P/OCF Ratio N/A

EV/Sales 11.20

EV/EBIT 66.83

EV/EBITDA 66.73

EV/FCF -15,986.52

Earnings Yield 4.8%

FCF Yield 0.0%

Adj. FCF Yield -1.2%

Financial Health

Net Debt $193.14M

Total Debt $754.44M

Cash & Short-Term Investments $552.25M

Total Assets $1.64B

Current Ratio 4.27

Quick Ratio 3.72

Debt / Equity Ratio 1.25

Debt / EBITDA 5.62

Debt / FCF -1,347.22

OCF / Debt -0.00

Interest Coverage 3.64

Altman Z-Score 5.54

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 82.4%

Operating Profit Margin 17.1%

EBITDA Margin 16.8%

Net Profit Margin 55.2%

FCF Margin -0.1%

Adj. FCF Margin -12.7%

SBC / Revenue 12.7%

SBC Impact (per share) -18055.7%

Returns

Return on Assets 26.9%

Return on Equity 72.3%

Return on Invested Capital 9.9%

Return on Capital Employed 9.9%

Return on Tangible Assets 26.9%

Historical Growth (CAGR)

Revenue CAGR 3Y 221.5%

Revenue CAGR 5Y 219.2%

Revenue CAGR 10Y 135.5%

EPS CAGR 3Y 86.5%

EPS CAGR 5Y 2042.9%

EPS CAGR 10Y 43.4%

FCF CAGR 3Y -1278.0%

FCF CAGR 5Y 75.9%

FCF CAGR 10Y 10.8%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 13

EPS Growth Next 3Y 11.7%

Revenue Growth Next 3Y 33.5%

Earnings Date Nov 1, 2026

EPS Estimate (next Q) $0.36

EPS Growth Est (next Q) -85.2%

Revenue Est (next Q) $247.06M

Revenue Growth Est (next Q) 52.8%

Fair Value Estimates

Graham Number $16.21

Graham Upside -71.6%

Lynch Fair Value $68.50

Lynch Upside 19.8%

Price Target $80.50

Price Target Upside 40.8%

Cash Flow

Operating Cash Flow $-18K

Free Cash Flow $-560K

Adj. Free Cash Flow $-101.67M

FCF Per Share $0

OCF Per Share $0

OCF/S Ratio 0.0%

Income Statement

Revenue $799.54M

Gross Profit $658.54M

Operating Income $136.33M

EBITDA $134.17M

Net Income $441.49M

EPS (Diluted) $2.74

Revenue / Employee $2M

Profit / Employee $1.11M

Employees 399